lifestyle.newsblaze.com

Author: ALX Oncology

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

April 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

April 17, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

April 13, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 27, 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

February 19, 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

February 19, 2026
ALX Oncology Announces Pricing of Underwritten Offering

January 30, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

January 30, 2026